Achieve Life Sciences Inc
$3.81
(as of Jun 24, 4:00 PM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Ticker Information for Achieve Life Sciences Inc
Stock Price
$3.81
Ticker Symbol
ACHV
Exchange
NASDAQ
Industry Information for Achieve Life Sciences Inc
Sector
Healthcare
Industry
Biotechnology
Company Description for Achieve Life Sciences Inc
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc., which is headquartered in Vancouver, Canada.
Fundamentals for Achieve Life Sciences Inc
Market Capitalization
$116,195,080
EBITDA
$-45,747,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-1.35
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
34,685,100
Percent Owned by Insiders
9.69%
Percent Owned by Institutions
41.59%
52-Week High
52-Week Low
Technical Indicators for Achieve Life Sciences Inc
Analyst Ratings for Achieve Life Sciences Inc
Strong Buy
7
Buy
1
Hold
0
Sell
0
Strong Sell
0
News About Achieve Life Sciences Inc
May 28, 2025, 8:30 AM EST
SEATTLE and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. See more.
May 13, 2025, 7:30 AM EST
Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025
See more.
Apr 21, 2025, 11:19 AM EST
ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo
See more.
Mar 11, 2025, 7:30 AM EST
Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025
See more.